Ignite Creation Date:
2024-05-06 @ 3:23 PM
Last Modification Date:
2024-10-26 @ 1:48 PM
Study NCT ID:
NCT04615962
Status:
UNKNOWN
Last Update Posted:
2020-11-04
First Post:
2020-10-25
Brief Title:
Topical Cream SNG100 for Treatment in Moderate Atopic Dermatitis Subjects
Sponsor:
Seanergy Dermatology Ltd
Organization:
Seanergy Dermatology Ltd
Study Overview
Official Title:
A Phase I Multicenter Double-Blind Randomized Study to Evaluate the Safety and Tolerability Profile of Topical Cream SNG100 for 14 Days of Treatment in Moderate Atopic Dermatitis Subjects
Status:
UNKNOWN
Status Verified Date:
2020-10
Last Known Status:
NOT_YET_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
SNG100
Brief Summary:
The investigators aimed to understand better the efficacy in a randomized double-blind intraindividual design trial in 66 participants with AD treated with SNG100 and 2 different strengths of topical steroids hydrocortisone and the medium potent mometasone furoate cream
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None